Tumor Progression, Regression, and Recurrence Monitoring using Hyperpolarized [1-13C]Pyruvate Metabolic Imaging in a Murine Breast Cancer Model
Peter jinwoo Shin1, Zihan Zhu1, Roman Camarda2, Robert Bok1, Alicia Zhou2, Andrei Goga2, and Daniel B Vigneron1

1Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, 2Biomedical Science Program, University of California, San Francisco, San Francisco, CA, United States

Synopsis

We used hyperpolarized [1-13C]pyruvate imaging to monitor tumor progression and regression in a murine breast cancer model that conditionally expresses the human c-MYC transgene in a doxycycline switchable manner. Previously, it was shown that this model could develop a secondary tumor even after the primary tumor regresses nearly fully following c-MYC deinduction. Hence, the purpose of this project was to monitor altered glycolytic metabolism by hyperpolarized metabolic MRI in this multi-stage mammary tumorigenesis animal model.

Purpose

The lactate dehydrogenase-A gene (LDH-A), whose product catalyzes the inter-conversion of pyruvate and lactate, is a known c-MYC-responsive gene1. We used hyperpolarized [1-13C]pyruvate imaging to monitor tumor progression and regression in a murine breast cancer model that conditionally expresses the human c-MYC transgene in a doxycycline switchable manner. Previously, it was shown that this model could develop a secondary tumor even after the primary tumor regresses nearly fully following c-MYC deinduction2. Hence, the purpose of this project was to monitor altered glycolytic metabolism by hyperpolarized metabolic MRI in this multi-stage mammary tumorigenesis animal model.

Methods

Tumor grafts derived from a human c-MYC transgenic mouse were transplanted into one of the mammary glands of normal female FVB mice. Following the transplant, the mice were fed with chows containing doxycycline (doxy-chow) for deregulated c-MYC expression from the onset. After the formation of palpable tumors, we performed a baseline [1-13C]pyruvate imaging study and removed the doxy-chow from the diet (off-doxy) for tumor regression. In the span of 7 weeks, follow up studies were performed at multiple time points (4, 16, 33, 49 days after the baseline). 1H images were also acquired to monitor morphological changes and to spatially register the 13C data. Changes in tumor volume over time were measured from the proton images.

Results

1) Morphological regression of the tumor (50% decrease in volume from the baseline) was observed as soon as 4 days after off-doxy (c-MYC deinduction) together with a 80% decreased lactate-to-pyruvate ratio (Figure 1). Lactate production further decreased until the 16th day as shown in the 13C spectra and the lac/pyr image. Then, on the 33rd day after off-doxy, an increase in the lactate-to-pyruvate ratio was observed, eventhough there were no apparent changes in the tumor volume at this point. Subsequently, a recurrent solid tumor mass was observed after 49 days post off-doxy with dramatically increased lactate production. 2) From a different animal, we observed a possible metastatic lesion forming in the mouse liver (44 days post off-doxy) together with a recurrent tumor in its primary tumor site (Figure 2). The 13C data showed high levels of alanine production only in the liver voxels.

Discussion

1) An increase in lactate-to-pyruvate ratio as measured by hyperpolarized [1-13C]pyruvate imaging was observed weeks before the formation of a secondary tumor, which recurred in a doxycycline independent manner. This observation suggets that when there is a secondary genetic mutation, of which LDH-A is a downstream target, then hyperpolarized metabolic MRI can detect the tumor recurrence much faster than conventional 1H anatomical imaging. 2) Previously, a high rate of conversion from pyruvate to alanine has been observed in pre-tumor stage of c-MYC-induced liver cancer mice3. Our data suggests that hyperpolarized [1-13C]pyruvate imaging is capable of detecting possible liver metastasis even when conventional 1H anatomical imaging fails to reveal the pathogenic lesions.

Conclusion

We observed that hyperpolarized [1-13C]pyruvate metabolic imaging could detect the in vivo glycolytic alterations that occur following c-MYC transgene induction/deinduction at different stages of mammary tumor formation.

Acknowledgements

This project is funded by NIH P41EB013598 grant.

References

1. Shim H, et al.. C-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997;94(13):6658-6663.

2. D’Cruz CM, et al.. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001;7:235-239.

3. Hu S, et al.. 13C-Pyruvate Imaging Reveals Alterations in Glycolysis that Precede c-Myc-Induced Tumor Formation and Regression. Cell Met. 2011;14:131-142.

Figures

13C monitoring of tumor progression and regression. Note the change in lac/pyr value between the 16 days and 33 days data showing altered metabolism that preceded the morphological change in the tumor. Inset values in the 1H images are the measured tumor volumes.

Liver lesion. a) Possible metastatic site within the liver (white dashed circle). b) HP 13C spectra showing increased levels of alanine production.



Proc. Intl. Soc. Mag. Reson. Med. 24 (2016)
0671